Revenue for Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current revenue (TTM) is $65.18B USD. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings (not a live revenue-per-second estimate).
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
LLY
Currently viewingRevenueSwitch metric
TTM (last 4 quarters)
$65.18B
YoY change
+44.7%
5Y CAGR
+21.6%
Peak year (2025)
$65.18B
Cumulative revenue
$683.63B
Revenue history chart for Eli Lilly (LLY) from 1985 to 2025
Revenue history table for Eli Lilly (LLY) from 1985 to 2025
| Fiscal year | Period ended | Reported | Revenue | YoY |
|---|---|---|---|---|
| 2025 | $65.18B | +44.7% | ||
| 2024 | $45.04B | +32.0% | ||
| 2023 | $34.12B | +19.6% | ||
| 2022 | $28.54B | +0.8% | ||
| 2021 | $28.32B | +15.4% | ||
| 2020 | $24.54B | +9.9% | ||
| 2019 | $22.32B | +3.8% | ||
| 2018 | $21.49B | +7.6% | ||
| 2017 | $19.97B | -5.9% | ||
| 2016 | $21.22B | +6.3% | ||
| 2015 | $19.96B | +1.7% | ||
| 2014 | $19.62B | -15.1% | ||
| 2013 | $23.11B | +2.3% | ||
| 2012 | $22.60B | -6.9% | ||
| 2011 | $24.29B | +5.2% | ||
| 2010 | $23.08B | +5.7% | ||
| 2009 | $21.84B | +7.2% | ||
| 2008 | $20.37B | +9.3% | ||
| 2007 | $18.63B | +18.8% | ||
| 2006 | $15.69B | +7.1% | ||
| 2005 | $14.65B | +5.7% | ||
| 2004 | $13.86B | +10.1% | ||
| 2003 | $12.58B | +13.6% | ||
| 2002 | $11.08B | -4.0% | ||
| 2001 | $11.54B | +6.3% | ||
| 2000 | $10.86B | +8.6% | ||
| 1999 | $10.00B | +8.3% | ||
| 1998 | $9.24B | +15.6% | ||
| 1997 | $7.99B | +14.1% | ||
| 1996 | $7.00B | +3.5% | ||
| 1995 | $6.76B | +18.4% | ||
| 1994 | $5.71B | -11.5% | ||
| 1993 | $6.45B | +4.6% | ||
| 1992 | $6.17B | +7.7% | ||
| 1991 | $5.73B | +10.3% | ||
| 1990 | $5.19B | +24.3% | ||
| 1989 | $4.18B | +2.6% | ||
| 1988 | $4.07B | +11.7% | ||
| 1987 | $3.64B | -2.1% | ||
| 1986 | $3.72B | +13.8% | ||
| 1985 | $3.27B | — |
Revenue values are taken from Eli Lilly's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Eli Lilly (LLY) reported revenue of $65.18B – surged 44.7% year-over-year.
Eli Lilly revenue compound annual growth for the 2020–2025 (5 years) window is +21.6%, sustaining 8 straight years of year-over-year growth.
The dataset's maximum revenue sits at $65.18B (2025); the minimum reading of $3.27B dates to 1985.
Among 8 Healthcare peers, Eli Lilly (LLY) ranks 4th; the peer median for revenue is $63.09B.
Eli Lilly Revenue by Year
Eli Lilly Revenue 2025: $65.18B
Eli Lilly revenue in 2025 was $65.18B, surged 44.7% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly Revenue 2024: $45.04B
Eli Lilly revenue in 2024 was $45.04B, surged 32.0% from 2023.
Eli Lilly Revenue 2023: $34.12B
Eli Lilly revenue in 2023 was $34.12B, grew 19.6% from 2022.
Eli Lilly Revenue 2022: $28.54B
Eli Lilly revenue in 2022 was $28.54B, edged up 0.8% from 2021.
Eli Lilly Revenue 2021: $28.32B
Eli Lilly revenue in 2021 was $28.32B.
See more financial history for Eli Lilly (LLY).
Sector peers — Revenue
Companies in the same sector as Eli Lilly, ranked by their latest revenue.
| Company | Revenue | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $447.57B | Healthcare |
| Novo Nordisk A/S (NVO) | $309.06B | Healthcare |
| Johnson & Johnson (JNJ) | $94.19B | Healthcare |
| Merck & Co., Inc. (MRK) | $65.01B | Healthcare |
| AbbVie Inc. (ABBV) | $61.16B | Healthcare |
| AstraZeneca PLC (AZN) | $58.74B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $44.56B | Healthcare |
| Amgen Inc. (AMGN) | $36.74B | Healthcare |
Frequently asked questions
What is Eli Lilly's revenue?
- Latest reported revenue for Eli Lilly (LLY) is $65.18B (period ending December 31, 2025).
How has Eli Lilly revenue changed year-over-year?
- Eli Lilly (LLY) revenue changed +44.7% year-over-year on the latest annual filing.
What is the long-term growth rate of Eli Lilly revenue?
- Eli Lilly (LLY) revenue compound annual growth rate is +21.6% over the most recent 5 years available.
When did Eli Lilly revenue hit its highest annual value?
- Eli Lilly revenue reached its highest annual value of $65.18B in 2025.
What was Eli Lilly revenue in 2024?
- Eli Lilly (LLY) revenue in 2024 was $45.04B.
What was Eli Lilly revenue in 2025?
- Eli Lilly (LLY) revenue in 2025 was $65.18B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
LLY Overview
Company profile, financial tools, and key metrics
LLY Revenue Counter
Earns $2,067 every second. See per minute, hour, and day.
LLY Earnings Counter
Earns $654.44 per second net profit. See per minute, hour, and day.
LLY Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
LLY What If Invested
What if you had invested $1,000? See historical returns from any date.
LLY How It Makes Money
Discover visual breakdown of $65.18B in revenue — where it comes from and where it goes.
LLY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
LLY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
LLY Daily Price Character
Steady · 48.0% historical win rate (green days). Streaks & record days.
LLY Buybacks
0.43% TTM buyback yield. Shareholder yield & SBC comparison.
LLY Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
LLY Dividend Profile
Yield: 0.73%. Safety: 8/8. See full history.
LLY Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
LLY Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.